Abionyx Pharma SA
Research Abionyx Pharma SA (ABNX) on Bullrun: market cap EUR 83.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABNX
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 83.80M
- Financial periodFY2025
- RevenueEUR 4.06M
- Revenue growth-10.7%
- Net income-EUR 5.55M
- Free cash flow-EUR 3.18M
- Gross margin13.1%
Valuation Snapshot
latest market cap is EUR 83.80M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 4.06M | -EUR 5.55M | -EUR 3.18M | 13.1% | -0.16 | EUR 3.52M | EUR 3.81M | EUR 4.51M |
| FY2024 | EUR 4.55M | -EUR 4.38M | -EUR 3.71M | 18.5% | -0.13 | EUR 3.24M | EUR 2.76M | EUR 7.52M |
| FY2023 | EUR 4.64M | -EUR 3.52M | -EUR 3.83M | 13.3% | -0.11 | EUR 4.10M | EUR 3.39M | EUR 7.92M |
| FY2022 | EUR 5.25M | -EUR 4.21M | -EUR 3.53M | 12.1% | -0.15 | EUR 4.05M | EUR 4.01M | EUR 7.17M |
| FY2021 | EUR 675.00K | -EUR 5.82M | -EUR 6.86M | 38.4% | -0.23 | EUR 7.94M | EUR 1.65M | EUR 10.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 83.80M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Abionyx Pharma SA's market cap?
Abionyx Pharma SA's market capitalization is EUR 83.80M.
What does Abionyx Pharma SA do?
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis.